Pharma Commercial Mock
← All views·CI feed·API docs
AASCO
Meeting Library
AACR Annual Meeting 2026 · San Diego, CA
11 shown of 8,238 total abstracts
  1. Abstract 64452026-04-04 · 16:45 CT · Arie Crown Theater
    Opdivo plus chemotherapy in previously untreated RCC: updated analysis from CheckMate-884
    S. Antonia, E. Winer, J. Cortes, et al. · Massachusetts General Hospital
    Education SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  2. Abstract 64822026-04-01 · 18:00 CT · S100A
    Quality of life outcomes with Opdivo in patients with RCC
    S. Peters, F. Andre, L. Paz-Ares · Vall d'Hebron Institute of Oncology
    Education SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  3. Abstract 63692026-04-02 · 16:15 CT · S100A
    KEYNOTE-332: Keytruda (pembrolizumab) 2L in RCC
    E. Winer, S. Antonia, S. Peters · Karolinska Institute
    Education SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  4. Abstract 68392026-04-01 · 21:00 CT · S100A
    Biomarker subgroup analysis of Keytruda in RCC (the KEYNOTE-503 study)
    P. Schmid, S. Antonia, J. Cortes · UCSF Helen Diller Family Comprehensive Cancer Center
    Education SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  5. Abstract 61882026-04-03 · 20:45 CT · E450
    KEYNOTE-350: Keytruda (pembrolizumab) adjuvant in RCC
    H. Rugo, R. Herbst, S. Tolaney, et al. · Princess Margaret Cancer Centre
    Education SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  6. Abstract 64972026-04-03 · 15:15 CT · Hall B1
    Real-world effectiveness of Opdivo vs standard of care in RCC
    J. Cortes, S. Antonia, H. Rugo · Royal Marsden Hospital
    Education SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  7. Abstract 69862026-04-04 · 20:15 CT · E450
    Long-term follow-up of Opdivo adjuvant for RCC: CheckMate-840
    A. Spira, S. Modi, R. Herbst, et al. · Karolinska Institute
    Education SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  8. Abstract 65772026-04-04 · 19:15 CT · Arie Crown Theater
    Quality of life outcomes with Keytruda in patients with RCC
    P. Schmid, C. Saura, T. Mok, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Education SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  9. Abstract 67642026-04-03 · 15:00 CT · S100A
    Biomarker subgroup analysis of Keytruda in RCC (the KEYNOTE-370 study)
    E. Winer, N. Rizvi · Royal Marsden Hospital
    Education SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  10. Abstract 63872026-04-02 · 18:15 CT · Hall B1
    KEYNOTE-90: Keytruda (pembrolizumab) adjuvant in RCC
    N. Rizvi, F. Andre, E. Winer, et al. · Mayo Clinic
    Education SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  11. Abstract 69412026-04-04 · 16:15 CT · S100A
    Biomarker subgroup analysis of Opdivo in RCC (the CheckMate-606 study)
    S. Tolaney, T. Mok, F. Andre, et al. · MD Anderson Cancer Center
    Education SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
© 2026 American Society of Clinical Oncology · Citations follow JCO supplement format:J Clin Oncol 44, 2026 (suppl 17; abstr XXXX). Demo mock.